AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04805944 — intervention group
Intervention type: DRUG
Intervention: Dolutegravir
Description: Dolutegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic et metabolite profiling, stools for microbiota profiling) drawn at follow-up.
Study NCT04805944 — intervention group
Intervention type: DRUG
Intervention: Bictegravir
Description: Bictegravir treated patients will be included and samples (blood for pharmacokinetic, pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
Study NCT04805944 — intervention group
Intervention type: DRUG
Intervention: Dolutegravir
Description: Patient having discontinued dolutegravir will be included and samples (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) drawn at follow-up.
Study NCT04805944 — intervention group
Intervention type: DRUG
Intervention: Dolutegravir
Description: Patients starting dolutegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of dolutegravir
Study NCT04805944 — intervention group
Intervention type: DRUG
Intervention: Bictegravir
Description: Patients starting bictegravir will be included and sampled both before (blood for pharmacogenetic and metabolite profiling, stools for microbiota profiling) and after (blood for pharmacokinetic and metabolite profiling, stools for microbiota profiling) the start of bictegravir
Study NCT05920915 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: non-interventional clinical research
Description: This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain
Study NCT05920915 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-interventional clinical research
Description: This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain
Study NCT05920915 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: non-interventional clinical research
Description: This study is a non-invasive clinical trial designed to observe the effect of applying cold to the neck area to effect of venous cannulation pain
Study NCT06107504 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sucralfate
Description: 2g of sucralfate powder and 1g of tranexamic acid powder will be sprayed after EST
Study NCT05829330 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Outpatient
Description: Outpatient Initiation of noninvasive mechanical ventilation
Study NCT05829330 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Hospitalization
Description: Initiation of non-invasive mechanical ventilation during hospitalization
Study NCT04989218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel combination of chemotherapy and immunotherapy
Description: This is a study of the combination of platinum based chemotherapy (gemcitabine and cisplatin) and doublet immunotherapy (durvalumab and tremelimumab) in the preoperative setting for intrahepatic cholangiocarcinoma with high risk features. Gemcitabine and cisplatin are chemotherapy agents used in the management of locally advanced and metastatic cholangiocarcinoma. Durvalumab is a programmed cell death ligand 1 (PDL1) blocking antibody, that improves the immune response against cancer. Tremelimumab is an antibody that targets cytotoxic T cell lymphocyte-associated protein 4 (CTLA4) on regulatory T cells. It also improves the immune response against cancer cells
Study NCT04889950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel C
Description: Tixel C )Novoxel®, Israel) is a thermomechanical system developed for fractional treatment. The system is designed for the treatment of soft tissue by direct conduction of heat, enabling tissue coagulation combined with micro ablation with low thermal damage to the surrounding tissue.
Study NCT04889950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow
Description: LipiFlow
Study NCT04592562 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: the Terumo Hydropearl® microspheres device
Description: Genicular artery embolization (GAE) is a new, minimally invasive investigational not yet approved therapy. In previous studies, this procedure has provided pain relief in patients with mild to moderate OA in the short to midterm. We will be utilizing the Terumo Hydropearl® microspheres particle beads during the GAE procedures. The procedure will take place utilizing fluoroscopic and ultrasound guidance. Following catheterization of the femoral artery, angiography of the affected limb will be performed to define the genicular arterial anatomy. Genicular arteries demonstrating abnormal vascularity and corresponding to the site of the patient's pain will be catheterized and embolized using microspheres. Prior to and after embolization, parametric imaging will be performed utilizing proprietary software to quantify changes in blood flow to the target area~The intended use of the Terumo Hydropearl® microspheres device is to embolize the geniculate artery branch.
Study NCT06397183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Strech with Traction (TSLR) Technique
Description: The Mulligan traction straight leg raise (TSLR) technique is a mobilization technique that can increase hamstring flexibility and range of motion.
Study NCT06397183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Isometric Relaxation Technique
Description: Post-Isometric Relaxation Technique is a Muscle Energy Technique which increases hamstring flexibility and range of motion.
Study NCT06312124 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Module
Description: Part 1 consists of an education module with premodule and postmodule assessment questionnaires.
Study NCT06312124 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Salpingectomy
Description: Part 2 consists of incorporating opportunistic salpingectomy /OS into non-gynecologic surgery
Study NCT06148948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1584862
Description: BI 1584862
Study NCT06565338 — intervention group
Intervention type: DRUG
Intervention: Dexmedetomidine
Description: drug
Study NCT04919681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Stretch exercises
Description: The intervention comprises of six weeks daily bi-lateral static stretching of the knee flexors. Stretches are performed seated on the ground. The participant sits upright on the floor with one leg straight. The sole of the other foot should be placed on the inside of the outstretched leg. The participant leans slightly forward, trying to touch their toes while maintaining full knee extension. Stretching is performed to the point of discomfort, and each stretch is held for 30-seconds for three repetitions.
Study NCT06148948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching BI 1584862
Study NCT06121284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Cycloserine
Description: Participants will orally ingest a capsule containing a 100mg dose of the antibiotic d-cycloserine daily (Monday-Friday) during 2 weeks of twice daily rTMS treatment (20 sessions) 60-120 minutes prior to the first rTMS treatment of the day.
Study NCT06121284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).
Study NCT06121284 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: intermittent Theta-Burst-repetitive Transcranial Magnetic Stimulation
Description: Repetitive Transcranial magnetic stimulation (rTMS) will be delivered using a MagPro X100 device with B70 coil and the intermittent theta burst (iTBS) protocol to the left dorsolateral prefrontal cortex. Participants will receive twice daily treatments (Monday-Friday) over two weeks (20-sessions).
Study NCT06121284 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Participants will orally ingest a capsule identical to that containing the study medication, however, this capsule will contain a placebo. They will ingest this capsule daily (Monday-Friday) for 2 weeks of twice-daily rTMS treatment (20 sessions) 60 - 120 minutes prior to the first rTMS treatment of the day.
Study NCT04550728 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Ankle robot training group
Description: Patients will be seated with the paretic foot strapped to the footplate the knee at full extension. The operator will set up and measure (using the robot) ankle passive DF and PF ROM limits. The robot training will include passive stretching, robot interactive game-based training, and cool-down stretching.
Study NCT04550728 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Ankle robot training and functional electrical stimulation(FES) group
Description: Patients will use the ankle robot device as the ankle training group. Also, water-based FES electrodes positioned inside a soft garment will be secured over the DF and PF muscles by wrapping the garment around the leg just below the knee joint. Stimulation intensity will be increased to maximal tolerance of each participant. Electrically induced contraction timing will be triggered by the ankle robot in synchrony with the ankle dorsi and plantar flexion movements.
Study NCT04560582 — intervention group
Intervention type: PROCEDURE
Intervention: Blood Draw
Description: Participants will have blood drawn for analysis at baseline and every 4 weeks for a total of 7 blood draws over 24 weeks.
Study NCT06152575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elranatamab
Description: Elranatamab will be administered subcutaneously
Study NCT06152575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elotuzumab
Description: Elotuzumab will be administered intravenously
Study NCT06152575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pomalidomide will be administered orally
Study NCT05883319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: manuel therapy
Description: approaches will be applied for 3 days / week for 6 weeks.
Study NCT06565338 — intervention group
Intervention type: DRUG
Intervention: Vitamin D3
Description: drug
Study NCT05883319 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercises
Description: approaches will be applied for 3 days / week for 6 weeks.
Study NCT05410535 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patients who continued UDCA 300mg medication
Description: patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
Study NCT05410535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patients who continued UDCA 300mg medication
Description: patients who continued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
Study NCT05410535 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patients who discontinued UDCA 300mg prescription
Description: patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
Study NCT05410535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients who discontinued UDCA 300mg prescription
Description: patients who discontinued UDCA 300mg prescription for the prevention of gallstone after PEGASUS-d trial
Study NCT06429371 — intervention group
Intervention type: OTHER
Intervention: Quantitative Sensory Testing
Description: Participants will undergo heat pain threshold, cold pain threshold, pressure pain threshold, temporal summation, and conditioned pain modulation to characterize pain sensitivity.
Study NCT05019703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT05019703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT06429371 — intervention group
Intervention type: OTHER
Intervention: Pain-Related Psychological Factors
Description: Participants will complete psychological questionnaires to characterize these factors.
Study NCT05390892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitor
Description: Empagliflozin, dapagliflozin, or canagliflozin
Study NCT05390892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GLP-1 receptor agonist
Description: Dulaglutide, liraglutide, semaglutide
Study NCT05296421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study NCT05296421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo surgery
Study NCT05296421 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uniformly-labeled [13C]glucose
Description: Given IV
Study NCT05552586 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: patients in the melatonin group will receive 60 mg/day Melatonin capsule (M1) from the day five before surgery.
Study NCT05552586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: patients will receive capsules of the same size and color
Study NCT06384807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-1510
Description: BHV-1510 will be administered as an IV infusion on Day 1 every 3 weeks
Study NCT06384807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: cemiplimab (350mg) will be administered as an IV infusion on Day 1 every 3 weeks
Study NCT06384807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BHV-1510
Description: BHV-1510 will be administered as an IV infusion on Day 1 every 2 weeks
Study NCT06395142 — intervention group
Intervention type: OTHER
Intervention: pedal walking
Description: Pedal walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation. A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during pedal walking in stroke participants.
Study NCT06395142 — intervention group
Intervention type: OTHER
Intervention: visual-deprivation walking
Description: visual-deprivation walking is a challenging task for stroke participants and can be used as a means of stroke rehabilitation.A cross-sectional study is conducted to investigate the real-time changes in plantar pressure and electroencephalogram during visual-deprivation walking in stroke participants.
Study NCT06152575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone will be administered orally
Study NCT06152575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bortezomib
Description: Bortezomib will be administered subcutaneously or intravenously
Study NCT06152575 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carfilzomib
Description: Carfilzomib will be administered intravenously
Study NCT06268678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phase of the menstrual cycle
Description: Follicular or luteal phase
Study NCT06059248 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the head in the sniffing position 
Description: Intubation was performed with the head in the  elevation  position
Study NCT04925700 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: ProDentis Lozenge
Description: 1-2 ProDentis Lozenges per day
Study NCT04925700 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Lozenge
Description: 1-2 Placebo Lozenges per day
Study NCT04788017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziresovir
Description: Planned treatments are:~* Cohort 1: 300 mg of ziresovir~* Cohort 2: up to 600 mg of ziresovir~* Cohort 3: up to 900 mg of ziresovir
Study NCT04788017 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Planned treatments are:~* Cohort 1: 300 mg of placebo~* Cohort 2: up to 600 mg of placebo~* Cohort 3: up to 900 mg of placebo
Study NCT05087732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STYLAGE® M Lidocaïne
Description: Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
Study NCT05087732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE® M Lidocaïne
Description: Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
Study NCT05087732 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: STYLAGE® M
Description: Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
Study NCT05087732 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: STYLAGE® M
Description: Up to 2 mL will be injected at Day 0 on a nasolabial fold and, if required, up to 1 mL could be injected 14 days after on the same nasolabial fold (touch-up).
Study NCT05911074 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: The Abbott Panbio™ COVID-19 Ag Rapid Test
Description: This is the intervention or medical device(s) intended to be used with a study participant according to the study protocol.
Study NCT06370702 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Handgrip Exercises
Description: Participants will firmly grip and squeeze the ball for 10 seconds, relax for 10 seconds and repeat for 10 minutes. They will be instructed to do this 3 times per day.
Study NCT05495451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting
Description: Multidisciplinary program will provide the teaching and supervision necessary to integrate the new knowledge and commitment to these lifestyle changes.
Study NCT05495451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate Mediterranean diet, Personalized exercice prescription and training, Intermittent fasting
Description: Multidisciplinary program will provide the teaching and supervision necessary to integrate the new knowledge and commitment to these lifestyle changes.
Study NCT04755868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: The Arm A (Experimental arm) Maintenance therapy with talazoparib (1mg once daily) (once daily 1.0 mg oral administration), 103patients
Study NCT04755868 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: The Arm B (Control arm) Maintenance therapy with placebo (once daily 1.0 mg oral administration), 103patients
Study NCT04289103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inolimomab (Leukotac)
Description: * Patient screening phase - Patients diagnosed with aGvHD will be identified. Only patients with SR-aGvHD will be finally included in the study.~* Treatment phase - Leukotac will be given up to D28~* Primary Follow-up phase - Patient's response (CR and PR) will be evaluated at D29 post inclusion. Patients will then be followed for survival, long-term safety and chronic GvHD occurrence during 6 months after inclusion.
Study NCT05908383 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMDTC for injection
Description: GMDTC for injection with a specification of 0.5g/vial, 250mg,500mg,850mg,1200mg,1600mg,2000mg, and administered by intravenous infusion. Using 0.9% physiological saline (0.5g will be prepared with 250mL injection solution to achieve a concentration of 2mg/mL). Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
Study NCT05908383 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.9% physiological saline for injection with a specification of 250ml/bag, and administered by intravenous infusion. Using an infusion pump at a rate of 4mL/min according to the dosage, and any infusion reactions will be recorded. The injection solution for both the experimental and placebo groups should be prepared by a non-blind investigator independent of the trial.
Study NCT04874909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sample
Description: Blood sample of 15ml max by subject (case, related individual, control) once time:~* subject less than 5 kg : 1.8 to 4.5 ml max~* subject 5 kg to 10 kg : 4.5 to 9 ml max~* subject 10 kg to 15 kg : 9 to 13.5 ml~* subject 15 kg to 20 kg : 13.5 to 15 ml max
Study NCT04874909 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Urine sample
Description: Urine sample (500 ml) once time
Study NCT05731024 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: close-loop synchronization controller with SPONT mode
Description: One-hour period where the pressure support of spontaneous breath will be automatically titrated based on pressure and flow waveform analysis obtained from the patient.
Study NCT05731024 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional synchronization settings with SPONT mode
Description: One-hour period where the pressure support of spontaneous breath will be manually set.
Study NCT05626348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iguratimod
Description: Iguratimod tablet，25mg, po, twice per day (Bid) prescribed at the beginning and adjusted due to patient response. Then may titer down until the endpoint.